Instil Bio (TIL) Depreciation & Amortization (CF) (2020 - 2026)
Instil Bio (TIL) posted quarterly Depreciation & Amortization (CF) of $12000.0 for Q1 2026, down 97.59% year-over-year from $498000.0 in Q1 2025, and little changed quarter-over-quarter from $12000.0 in Q4 2025.
Instil Bio (TIL) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Instil Bio's Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $12000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 97.59% year-over-year to $12000.0; the TTM figure through Mar 2026 stood at $48000.0 (down 98.46% YoY), while the FY2025 annual figure was $534000.0, down 85.21% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $12000.0, roughly flat from $12000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $2.1 million in Q4 2022, with the low at $12000.0 in Q2 2025.
- The 5-year median for Depreciation & Amortization (CF) is $953000.0 (2023), against an average of $876411.8.
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) soared 153.8% in 2022, then plunged 98.77% in 2025.
- Instil Bio's Depreciation & Amortization (CF) stood at $2.1 million in 2022, then slumped by 50.64% to $1.0 million in 2023, then fell by 28.47% to $741000.0 in 2024, then tumbled by 98.38% to $12000.0 in 2025, then changed by 0.0% to $12000.0 in 2026.
- Business Quant data shows TIL's Depreciation & Amortization (CF) at $12000.0 in Q1 2026, $12000.0 in Q4 2025, and $12000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Instil Bio | 51.68 Mn | 51.68 Mn | - | 248,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 248,000.00 |
| Jun 30, 2026 | 248,000.00 |
| Mar 31, 2026 | 12,000.00 |
| Mar 31, 2026 | 12,000.00 |
| Dec 31, 2025 | 12,000.00 |
| Dec 31, 2025 | 12,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Jun 30, 2025 | 12,000.00 |
| Jun 30, 2025 | 12,000.00 |
| Mar 31, 2025 | 498,000.00 |
| Mar 31, 2025 | 498,000.00 |
| Dec 31, 2024 | 741,000.00 |
| Dec 31, 2024 | 741,000.00 |
| Sep 30, 2024 | 901,000.00 |
| Sep 30, 2024 | 901,000.00 |
| Jun 30, 2024 | 975,000.00 |
| Jun 30, 2024 | 975,000.00 |
| Mar 31, 2024 | 993,000.00 |
| Mar 31, 2024 | 993,000.00 |